Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Glutamic acid may help lessen or prevent nerve damage caused by vincristine. It is
not yet known whether glutamic acid is more effective than a placebo in preventing nerve
damage in patients receiving vincristine for Wilms' tumor, rhabdomyosarcoma, acute
lymphoblastic leukemia, or non-Hodgkin's lymphoma.
PURPOSE: This randomized phase III trial is studying glutamic acid to see how well it works
compared to a placebo in reducing nerve damage caused by vincristine in young patients
receiving vincristine for Wilms' tumor, rhabdomyosarcoma, acute lymphoblastic leukemia, or
non-Hodgkin's lymphoma.
Phase:
Phase 3
Details
Lead Sponsor:
University of South Florida
Collaborators:
Children's Oncology Group National Cancer Institute (NCI)